Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.
about
A systematic evaluation of factors associated with nocturia--the population-based FINNO studyCurrent medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitationsTotal urgency and frequency score as a measure of urgency and frequency in overactive bladder and storage lower urinary tract symptomsAdverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approachPerformance of the American Urological Association Symptom Index with and without an additional urge incontinence item.A review of RCTs in four medical journals to assess the use of imputation to overcome missing data in quality of life outcomes.A retrospective study of treatment persistence and adherence to α-blocker plus antimuscarinic combination therapies, in men with LUTS/BPH in the Netherlands.Twelve-week, prospective, open-label, randomized trial on the effects of an anticholinergic agent or antidiuretic agent as add-on therapy to an alpha-blocker for lower urinary tract symptoms.Management of male urinary incontinence.Medical management of overactive bladderChanges in initial expenditures for benign prostatic hyperplasia evaluation in the Medicare population: a comparison to overall Medicare inflationBenign Prostatic Hyperplasia Implications for Pharmacologic Treatment and Perioperative Care.Tolterodine extended release in the treatment of male OAB/storage LUTS: a systematic review.Tolterodine extended-release for overactive bladder.Efficacy of propiverine ER with or without α-blockers related to maximum urinary flow rate in adult men with OAB: results of a 12-week, multicenter, non-interventional study.The role of combination medical therapy in benign prostatic hyperplasia.Efficacy and safety of low-dose propiverine in patients with lower urinary tract symptoms/benign prostatic hyperplasia with storage symptoms: a prospective, randomized, single-blinded and multicenter clinical trial.Prospective pharmacologic therapies for the overactive bladderOveractive bladder in malesNaftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasia.Lower urinary tract symptoms in men.A current perspective on geriatric lower urinary tract dysfunction.Combination therapies for the management of nocturia and its comorbiditiesThe association of nocturia with incident falls in an elderly community-dwelling cohort.A modified approach to patient's selection with improved clinical outcomes in sacral nerve modulation.Cost-effectiveness of a fixed-dose combination of solifenacin and oral controlled adsorption system formulation of tamsulosin in men with lower urinary tract symptoms associated with benign prostatic hyperplasia.Comparative Effectiveness and Safety of Monodrug Therapies for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Network Meta-analysis.Urologic medications and ophthalmologic side effects: a review.Add-on anticholinergic therapy for residual nocturia in patients with lower urinary tract symptoms receiving α1-blocker treatment: a multi-centre, prospective, randomised study.New medical treatments for lower urinary tract symptoms due to benign prostatic hyperplasia and future perspectivesVarious treatment options for benign prostatic hyperplasia: A current update.Efficacy and Safety of Initial Combination Treatment of an Alpha Blocker with an Anticholinergic Medication in Benign Prostatic Hyperplasia Patients with Lower Urinary Tract Symptoms: Updated Meta-Analysis.The dilemma of nocturiaBenign prostatic hyperplasia and lower urinary tract symptom guidelinesEvidence-based guidelines for the treatment of lower urinary tract symptoms related to uncomplicated benign prostatic hyperplasia in Italy: updated summary from AURO.itEffects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions.PDE5 inhibitors beyond erectile dysfunction.Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia.Tamsulosin MR and OCAS (modified release and oral controlled absorption system): current therapeutic uses.The safety and efficacy of tolterodine extended release in the treatment of overactive bladder in the elderly
P2860
Q24289211-441AB391-D457-41AD-A298-93425E7EDEC8Q24649617-4F7F5BB6-74D1-457C-B2DE-2BB3644BE12EQ27001248-E8FF5CC9-BD6C-4FD3-B1E9-11D504F96EF4Q28742444-17BC3BC8-8A18-4E25-9712-4AE0BCC3A128Q30425356-337C7262-D299-4A73-AC96-E5D3D4F0A3A8Q31171052-2E34AE0C-E2C4-4D3B-9DF8-85E9A15776A7Q33716568-1A01CD22-0303-40DB-8659-6024A9836C0DQ33904553-1DB174FD-36C9-4107-B39F-5E82BF1B7C76Q34124025-2EFAC706-177A-4E41-B1ED-8D183E6160F4Q34124065-8DCC4B82-DB85-4EC0-86FD-372F994C0B60Q34198543-00A67CC3-3323-43CF-B299-283C29AEA38FQ34338110-2E044727-2DB5-4765-81B2-DAD912523226Q34502903-758DF544-1D63-4B6B-B08D-1694EAB2E598Q34610640-DDAD47CA-91A2-4A98-BE15-EDB6DC55ABDFQ34709479-23436396-F7C9-40AC-AB4D-C38CC7119C24Q34877827-1D7A27F4-37CD-4DB6-8E58-2662EF3341C2Q34900162-27561D5F-AECE-4F13-964F-C9F74CD19D44Q35076367-66D400A3-0301-4210-AD62-649D1E95D250Q35076391-7EACDD72-55DB-424B-B56A-66FBE96E28E6Q35093140-EE591335-EB03-4A5E-9D23-C8AA044EF308Q35225398-5C091947-CE77-4641-BBC4-8A2FCDC5B7DEQ35348864-DF14E76A-34F4-40BD-9642-70A9F2084367Q35535376-B5C0ADA4-7697-48EA-9ECA-7E8810995465Q35568092-498DB695-58F6-49CC-BEF2-813F839A3D29Q35605722-02D355BC-13C2-4044-A507-147676543F1CQ35625741-CC612B63-7D18-4305-8E96-53902D5CE4DDQ35689075-91D0E90B-7E7D-4E4C-8D67-7BC3760BA124Q35788323-16413EAD-BB1F-4EA3-89B8-1387B776AC48Q36012645-89F1616D-ADC0-4393-A3B1-F4C927D1308BQ36133212-14255599-E1AF-48C6-9324-BB4ADD7BBE25Q36181722-0DC93200-E8C6-432F-9E77-3ADB5C80D45BQ36245584-40DD5253-2F09-429C-BA9C-3C1D97C10C2EQ36349753-1A126DFA-66CA-4B88-8397-E89389C3244BQ36349764-C8215CEF-6817-4A85-99C6-CFEA5B4BFB02Q36379355-FCFDB57C-836A-4155-9F01-A0520576DE90Q36432096-F3414021-EA7B-4799-A67C-0A109A5C49B6Q36878017-D42E8D1A-9F3A-4D48-B5B2-F9A6B3A24C2BQ37092262-825F4400-8CF8-4D12-890E-2906498E6385Q37111860-09A1FBDE-B003-4EA7-9EA5-656DE3E507B8Q37199946-C85144C5-18DB-42C9-9D92-091016E36A0A
P2860
Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.
description
2006 nî lūn-bûn
@nan
2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Tolterodine and tamsulosin for ...... a randomized controlled trial.
@ast
Tolterodine and tamsulosin for ...... a randomized controlled trial.
@en
Tolterodine and tamsulosin for ...... a randomized controlled trial.
@nl
type
label
Tolterodine and tamsulosin for ...... a randomized controlled trial.
@ast
Tolterodine and tamsulosin for ...... a randomized controlled trial.
@en
Tolterodine and tamsulosin for ...... a randomized controlled trial.
@nl
prefLabel
Tolterodine and tamsulosin for ...... a randomized controlled trial.
@ast
Tolterodine and tamsulosin for ...... a randomized controlled trial.
@en
Tolterodine and tamsulosin for ...... a randomized controlled trial.
@nl
P2093
P356
P1476
Tolterodine and tamsulosin for ...... a randomized controlled trial.
@en
P2093
Claus G Roehrborn
Eric S Rovner
Martin Carlsson
Steven A Kaplan
Tamara Bavendam
Zhonghong Guan
P304
P356
10.1001/JAMA.296.19.2319
P407
P577
2006-11-01T00:00:00Z